Zurich Cantonal Bank’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-3,415
| Closed | -$129K | – | 2651 |
|
|
2021
Q1 | $129K | Buy |
+3,415
| New | +$85.2K | ﹤0.01% | 2018 |
|
|
2019
Q4 | – | Sell |
-1,753
| Closed | -$7K | – | 2648 |
|
|
2019
Q3 | $7K | Hold |
1,753
| – | – | ﹤0.01% | 2586 |
|
|
2019
Q2 | $11K | Hold |
1,753
| – | – | ﹤0.01% | 2564 |
|
|
2019
Q1 | $23K | Hold |
1,753
| – | – | ﹤0.01% | 2382 |
|
|
2018
Q4 | $16K | Hold |
1,753
| – | – | ﹤0.01% | 2499 |
|
|
2018
Q3 | $24K | Hold |
1,753
| – | – | ﹤0.01% | 2447 |
|
|
2018
Q2 | $28K | Hold |
1,753
| – | – | ﹤0.01% | 2358 |
|
|
2018
Q1 | $30K | Hold |
1,753
| – | – | ﹤0.01% | 2303 |
|
|
2017
Q4 | $38K | Buy |
1,753
+1,037
| +145% | +$33.3K | ﹤0.01% | 2202 |
|
|
2017
Q3 | $29K | Sell |
716
-3,599
| -83% | -$113K | ﹤0.01% | 2120 |
|
|
2017
Q2 | $130K | Sell |
4,315
-15,715
| -78% | -$491K | ﹤0.01% | 1204 |
|
|
2017
Q1 | $724K | Buy |
20,030
+1,302
| +7% | +$57.4K | 0.01% | 827 |
|
|
2016
Q4 | $938K | Sell |
18,728
-78,287
| -81% | -$4.11M | 0.01% | 795 |
|
|
2016
Q3 | $5.09M | Buy |
97,015
+17,770
| +22% | +$849K | 0.05% | 387 |
|
|
2016
Q2 | $3.28M | Buy |
79,245
+4,531
| +6% | +$197K | 0.04% | 419 |
|
|
2016
Q1 | $3.04M | Buy |
74,714
+30,625
| +69% | +$1.05M | 0.04% | 427 |
|
|
2015
Q4 | $1.83M | Buy |
44,089
+2,175
| +5% | +$72.9K | 0.02% | 558 |
|
|
2015
Q3 | $645K | Buy |
+41,914
| New | +$901K | 0.01% | 785 |
|
Zurich Cantonal Bank's FPRX Position: Q2 2021 in Review
Zurich Cantonal Bank sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 3,415 shares — an estimated $129K sold.
Zurich Cantonal Bank first reported a position in FPRX in Q3 2015 and held it in 18 quarters. The position peaked at $5.09M in Q3 2016. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Zurich Cantonal Bank reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Zurich Cantonal Bank sold 3,415 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $129K.
- Zurich Cantonal Bank first reported a position in Five Prime Therapeutics, Inc. in Q3 2015 and held it in 18 quarters.
- Zurich Cantonal Bank's Five Prime Therapeutics, Inc. position peaked at $5.09M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Zurich Cantonal Bank's 13F filing for Q2 2021, filed 30 Jul 2021.